{
  "source": "PA-Med-Nec-Cobenfy.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2360-1\nProgram Prior Authorization/Medical Necessity\nMedication Cobenfy™ (xanomeline and trospium chloride)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nCobenfy is FDA approved for the treatment of schizophrenia. This program requires a member to try\nthree atypical antipsychotics before providing coverage for Cobenfy.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Cobenfy will be approved based on ONE of the following criteria:\na. BOTH of the following:\n1) Diagnosis of schizophrenia\n-AND-\n2) History of failure, contraindication, or intolerance to three of the following (please\ndocument drug, date and duration of trial):\n(a) aripiprazole (generic Abilify)\n(b) olanzapine (generic Zyprexa)\n(c) quetiapine IR or ER (generic Seroquel or Seroquel XR)\n(d) risperidone (generic Risperdal)\n(e) ziprasidone (generic Geodon)\n-OR-\nb. Treatment with Cobenfy was initiated at a recent behavioral inpatient admission\n(discharge within the past 3 months) and the member is currently stable on therapy.\n(Please document date of discharge from inpatient admission).\n-OR-\nc. Member is new to the plan and currently stabilized on Cobenfy (as evidenced by\ncoverage effective date of less than or equal to 120 days)\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\nB. Reauthorization\n1. Cobenfy will be approved for continuation of therapy based on the following criterion:\na. Documentation of a positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes",
    "pply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and Prior Authorization/Notification may also be in place.\n4. References:\n1. Cobenfy [package insert]. Princeton, NJ: E.R. Squibb & Sons, LLC. September 2024.\n2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with\nSchizophrenia Third Edition. Available at:\nhttps://psychiatryonline.org/doi/10.1176/appi.books.9780890424841\nProgram Prior Authorization/Medical Necessity - Cobenfy\nChange Control\n1/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}